Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets.
Danni QuanRuilin HouHongming ShaoXinqi ZhangJianqiang YuWannian ZhangHongbin YuanChun-Lin ZhuangPublished in: Journal of medicinal chemistry (2023)
Systemic inflammatory response syndrome (SIRS), characterized by severe systemic inflammation, represents a major cause of health loss, potentially leading to multiple organ failure, shock, and death. Exploring potent RIPK1 inhibitors is an effective therapeutic strategy for SIRS. Recently, we described thio-benzoxazepinones as novel RIPK1 inhibitors and confirmed their anti-inflammatory activity. Herein, we further synthesized novel thio-benzoxazepinones by introducing substitutions on the benzene ring by an alkynyl bridge in order to extend the chemical space from the RIPK1 allosteric to ATP binding pockets. The in vitro cell and kinase assays found that compounds 2 and 29 showed highly potent activity against necroptosis (EC 50 = 3.7 and 3.2 nM) and high RIPK1 inhibitory activity ( K d = 9.7 and 70 nM). Prominently, these two analogues possessed better in vivo anti-inflammatory effects than the clinical candidate GSK'772 and effectively blocked hypothermia and deaths in a TNFα-induced SIRS model.
Keyphrases
- inflammatory response
- small molecule
- binding protein
- photodynamic therapy
- healthcare
- public health
- cardiac arrest
- drug induced
- rheumatoid arthritis
- single cell
- brain injury
- signaling pathway
- lipopolysaccharide induced
- protein kinase
- stem cells
- early onset
- mental health
- dna binding
- high throughput
- high glucose
- protein protein
- diabetic rats
- cell therapy
- tyrosine kinase
- lps induced
- anti inflammatory
- health information
- toll like receptor
- mesenchymal stem cells
- immune response
- risk assessment
- bone marrow